antituberculosis drug

antituberculosis drug

Infectious disease Any drug–eg, isoniazid, rifampin, ethambutol, streptomycin, pyrazinamide, ethionamide, para-aminosalicylic acid, kanamycin, cycloserine, capreomycin, ciprofloxacin, amikacin, used to manage TB; multidrug-resistant isolates of M tuberculosis are most often resistant to isoniazid and rifampin. See Drug-resistant tuberculosis.
References in periodicals archive ?
Primary antituberculosis drug resistance and acquired rifampicin resistance in Gujarat, India.
Beginning in January 1993, TB surveillance was expanded to collect additional information concerning each case, including results of human immunodeficiency virus (HIV)-antibody testing, occupation, history of substance abuse, homelessness, residence in a correctional or long-term--care facility, initial antituberculosis drug therapy and results of drug-susceptibility testing (3).
Khuller, "Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model," Journal of Antimicrobial Chemotherapy, vol.
Rawat, "Antituberculosis drug research: a critical overview," Medicinal Research Reviews, vol.
The IRL, Ahmedabad got WHO accreditation in March 08 for Lowenstein-Jensen solid culture and first line antituberculosis drug sensitivity.
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines.
In the study by Park et al., previous ofloxacin use was not associated with ofloxacin resistance or with other antituberculosis drug resistance.
The patient was switched to antituberculosis drug therapy, and his improvement was dramatic.
Should moxifloxacin be substituted for isoniazid as a first-line antituberculosis drug? Am J Respir Crit Care Med 2009; 180 : 686; author reply 686-7.
The patient was started on antituberculosis drug therapy, but he died within 2 weeks of treatment.
In a previous survey, conducted in Taiwan during 2000-2008, we found the rate of antituberculosis drug resistance to be lower for older patients than for younger patients (2); however, current information about the patient characteristics associated with isoniazid-resistant tuberculosis (TB) in Taiwan is lacking.
Chapter 1 provides updated information from a survey of the network of supranational reference laboratories to determine the prevalence of XDR-TB among strains sent for drug susceptibility testing (DST) in addition to new data from the WHO/IUATLD Global Project on Antituberculosis Drug Resistance Surveillance.